An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Hydration is an important part of preventing and treating sickle cell crises, writes columnist Oluwatosin Adesoye, who shares ...